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Abstract
Objectives: Viscosupplementation with new-generation, polyol-containing, cross-linked hyaluronic acid (HA)
gels reduces joint inflammation in patients with knee osteoarthritis. Gait analysis is a complementary outcome
measure to standard patient-reported scores and physical measures for testing the effect of HA injection. This
three-arm, prospective, randomized, controlled, double-blind, feasibility pilot study investigated which gait
parameters are more sensitive following a single bolus injection of polyol-containing HA for knee
osteoarthritis.
Methods: Twenty-two patients with Ahlbäck grade II–III knee osteoarthritis were randomly allocated into
three groups: (1) HA + mannitol (n = 9), (2) HA + sorbitol (n = 5), and (3) saline placebo (n = 8). Patients were
assessed by blinded observers prior to injection and at 4 weeks post-injection (4W). Outcome measures
included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Society score
(KSS), EuroQol in five-dimensions (EQ-5D), VAS pain, and VAS stiffness. Gait was assessed over 30 m using a
portable inertial-based data logger (Physilog®).
Results: Differences between 4W and baseline were statistically significant for the mannitol-containing viscosupplement,
with a median increase of 0.076m/s on gait speed (p = 0.039), 0.055m on stride length (p = 0.027), and 15 points on the
KSS (p = 0.047). In contrast, the HA + sorbitol and saline groups demonstrated no significant changes from baseline to 4W
in any gait parameters or self-reported outcome measures (all p > 0.3). The observed increase in gait speed is
approximately 13% greater than the mean difference between healthy subjects and those with knee osteoarthritis, is
clinically important, and thus is a sensitive gait parameter.
Conclusions: This study demonstrated gait speed and stride length are the most relevant gait parameters to investigate
when assessing the effect of polyol-containing HA viscosupplementation. This study supports the need for a larger,
randomized, controlled, clinical trial to assess the effect of a single-bolus HA injection versus multiple injections in people
with knee osteoarthritis using both gait performance and self-reported parameters of knee function.
Trial registration: This study was retrospectively registered at clinicaltrials.gov on August 20, 2018, and assigned
#NCT03636971.
Level of evidence: I
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Introduction
Knee osteoarthritis (OA) represents significant cost to so-
ciety as a result of work absenteeism and treatment regi-
mens [1, 2]. Options to alleviate pain and restore function
include analgesics, anti-inflammatories, physiotherapy,
viscosupplementation, and joint replacement for later
stages of the disease [3]. Viscosupplementation consists of
intra-articular injection of a hyaluronic acid (HA) com-
pound that acts as a lubricant and shock absorber to in-
crease resilience and promote joint health [4]. HA is a
non-sulfated physiological linear glycosaminoglycan found
in synovial fluid (3500mg/kg) and cartilage surrounding
chondrocyte cells (1200mg/kg) [5]. HA maintains extra-
cellular structure by holding moisture and maintaining
viscoelasticity of tissue [4]. In cartilage, HA aggregates in
the presence of aggrecan, hyaluronan and proteoglycan
link protein 1 (HAPLN1), and water to provide adequate
resistance to joint compression [6].
HA molecules in cartilage decrease in molecular weight
with age, resulting in less support to the extracellular
matrix [7]. Oxygen free radicals, found in diseased joints,
depolymerize HA into oligosaccharides, which have a
different viscosity and protective properties compared to
normal synovial fluid [8]. Chemical modifications of visco-
supplements with polyol free radical scavengers such as
sorbitol and mannitol have been proposed to eliminate the
oxygen free radicals found in diseased joints [9, 10]. These
new generation non-crosslinked gels have a reduced risk of
allergic reactions compared to HA derived from traditional
sources such as rooster’s comb, chicken cartilage, or micro-
bial fermentation have longer HA chains and a higher vis-
cosity than first-generation in vitro-produced HA and lack
a non-naturally occurring motif found in crosslinked HA
that may trigger an immune reaction. The presence of a
polyol stabilizes the HA and reduces joint inflammation.
Consequently, new generation viscosupplements are ex-
pected to be more effective in diminishing the signs of joint
inflammation [11].
Several systematic reviews have compared the ef-
fectiveness of viscosupplementation with placebo
intervention [12]. However, these reviews evaluated
trials using viscosupplements which have been com-
mercially available for many years and did not include
the newer generation of viscosupplements character-
ized by the presence of a polyol (i.e., sorbitol, manni-
tol) and higher concentrations of HA. Furthermore,
new generation viscosupplements tend to be used in
a “one-shot” injection clinical protocol. A single bolus
has been demonstrated to trigger less inflammation
and a reduced antibody response when compared to a
series of three injections. [13] “One-shot” administra-
tion may offer other advantages in clinical settings as
well, including a lower risk of infection, reduced cost,
and improved convenience for the patient.
The effectiveness of viscosupplementation remains
controversial. While the American Association of Ortho-
pedic Surgeons (AAOS) and the National Institute for
Health and Clinical Excellence (NICE) “cannot recom-
mend using hyaluronic acid for patients with symptom-
atic OA of the knee” [14, 15], the European League
Against Rheumatism (EULAR) advocates that “there is
evidence to support the efficacy of HA in the manage-
ment of knee OA, both for pain reduction and func-
tional improvement” [16]. This debate is believed to be
partially driven by the heterogeneity of the products cur-
rently being used and the incomplete understanding of
how HA injections provide a therapeutic action [17]. A
recent review described the mechanical and pharmaco-
logical stages of the proposed mechanism of exogenous
HA activity in the knee [18].
The Osteoarthritis Society Research International
(OARSI) recommends patient-reported and physical
performance measures when conducting trials in OA
[19]. Physical performance has traditionally been
assessed by the timed up and go test, the 6-min walk-
ing test, and the stair climbing test [20]. Gait analysis
has received less attention in trials studying the ef-
fects of viscosupplementation. Numerous studies have
reported differences in gait biomechanics between
people with knee OA and healthy controls [21]. Thus,
analyzing gait may give rise to new perspectives when
studying different therapeutic approaches. There is a
paucity of trials that have studied the effects of
one-shot polyol-containing viscosupplements on hu-
man gait.
The aim of this prospective, randomized, controlled,
feasibility, clinical pilot study was to determine the most
relevant gait parameters and clinical outcome measures
when assessing the effectiveness of polyol-containing
HA injection in people with knee OA.
Patients and methods
This investigation was conducted in a university hospital
setting. Patients with a diagnosis of primary OA of the
knee, Ahlbäck grade II or III, and who provided in-
formed consent were included. Exclusion criteria were a
recent history of infection, diabetes, neurological impair-
ment, chronic venous or lymphatic stasis, pain medica-
tion of level 2, 3, or 4 according to the World Health
Organization analgesic ladder, [22] psychiatric condi-
tions, contraindications for HA joint injection, and HA
or steroid injections within the last 6 months.
At the initial screening appointment, all patients
underwent an X-ray to determine the grade of OA. If all
inclusion and exclusion criteria were respected, consecu-
tive patients were invited to participate in the study. Fol-
lowing their approval, patients were contacted by
telephone to schedule an appointment for the injection.
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On the first day, prior to the injection, patients under-
went the baseline clinical assessment (i.e., outcome
measure questionnaires and gait analysis), which was
performed by a clinician blinded to the injection
randomization. Patients were assigned to one of three
groups according to a previously developed, computer
generated, randomization key [23] and then received the
injection. Each patient received one injection of either
HA +mannitol (1800kD, Ostenil Plus®, TRB Chemedica
SA, Switzerland) (group 1), or HA + sorbitol (2000 kD,
Synolis®, Gebro-Pharma AG, Switzerland) (group 2), or
the same volume of saline (group 3). Injections were
conducted with a lateral approach by physicians who
were advised of the product to be used immediately
prior to the injection. The two physicians responsible for
the injections did not participate in data collection or
data analysis. Patients were reassessed by an independ-
ent observer at 4 weeks post-injection (4W), which is
routine for all patients at our institution. The clinicians
conducting the 4W follow-up were blinded to baseline
scores and the product injected. Patient recruitment for
this study began in May 2013, and the last follow-up ap-
pointment was completed in February 2015.
Outcome measures included the visual analog scale
(VAS) question of the EuroQol in five dimensions ques-
tionnaire (EQ-5D-VAS) [24], VAS pain, VAS stiffness,
the Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC), [25], and the Knee Society
score (KSS) [26]. The clinicians at our institution are fa-
miliar with these tools. Patients’ gait was assessed during
two 30m walks along an indoor corridor at each pa-
tient’s preferred speed. Patients were instructed to walk
normally, and no verbal encouragement was given dur-
ing the test. Miniature inertial sensors were mounted on
the trunk (sacrum) and each thigh and shank to measure
lower limb and trunk rotations, and these were linked to
a portable data logger (Physilog, BioAGM, Switzerland).
Temporal and spatial parameters were computed to de-
termine four basic gait parameters: walking speed, stride
length, cadence, and duration of the swing phase relative
to the cycle duration, which were the primary outcomes
for this study. These parameters were measured over the
30m of the two trials according to a previously validated
protocol [27]. Patients were asked directly about adverse
events by the outcomes assessor at 1 day, 1 week, and
4W post-injection.
Research Ethics Board approval was obtained to con-
duct this randomized, controlled, clinical pilot study
(CER-VD No 273/13).
Data collection and analysis
The gait parameters measured in each cycle of the two
walks were averaged during the steady part of the walks
to provide a single measure of speed, stride length,
cadence, and swing duration for each patient at baseline
and at 4W. The changes between baseline and 4W were
calculated individually for each patient, for the four gait
parameters and five clinical outcome measure scores.
Medians and interquartile ranges were used to report
the changes from baseline to 4W within each patient
group, as changes did not follow a normal distribution.
Wilcoxon signed-rank tests were used to compare base-
line and 4W measures.
For this exploratory, prospective, randomized, double-blind,
pilot study, a minimal sample size of twenty patients
was selected to determine the feasibility of the trial
design and select appropriate outcome measures for a
future larger trial (Fig. 1). The limited sample size in
this study did not allow for comparison of changes
between patient groups.
All statistical analyses were performed with Matlab
(Release 2014b, The MathWorks, USA) using a signifi-
cance level set a priori to 5%.
Results
Overall, 22 injections were performed: 9 in group 1 (HA
+mannitol), 5 in group 2 (HA + sorbitol) and 8 in group 3
(saline control). Twelve patients were male and ten were
female. Patients had a mean (standard deviation) age of
53.5 (11.89) years and BMI of 28.4 (4.1) kg/m2 (Table 1).
Gait parameters before and 4W after injection are
summarized in Table 2.
Changes in walking speed and stride length from baseline
to 4W were statistically significant for the HA+mannitol
group, with median increases of 0.076m/s (p = 0.039) and
0.055m (p = 0.027), respectively (Fig. 2). Changes in ca-
dence (p = 0.30) and in swing phase duration (p = 0.43)
were not statistically different for the HA +mannitol group
(Fig. 2). There were no statistically significant changes from
baseline to 4W in any gait parameters in the HA+ sorbitol
and saline groups (p > 0.3).
With respect to the clinical outcome measures, the
change in KSS score from baseline to 4W was statisti-
cally significant for the HA +mannitol group, with a me-
dian increase of 15 points (p = 0.047) (Fig. 3). Changes in
the other clinical scores for the HA +mannitol group
and in all scores for the two other groups were not sta-
tistically significant (p > 0.1).
No adverse reactions were observed.
Discussion
This prospective, randomized, controlled, exploratory
pilot study found that gait speed and stride length are
the most relevant gait parameters to investigate when
assessing the effects of HA injection in people with
knee OA.
A search of the literature produced seven trials that
evaluated gait analysis following HA knee injection [28–
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34]. Two studies were excluded from further review: one
focused on EMG muscular patterns; [33] the other [35]
was a secondary report of a population already described
elsewhere [29]. The five remaining trials were heteroge-
neous for the study design, outcomes chosen, methods
of data collection, and substances delivered. Gait data
were collected with a six-camera setup in two studies
[29, 34], an eight-camera setup in one study [30], and a
10-m walkway system in another [31]. In the fifth study,
Lester and Zhang [32] used a portable device with five
inertial sensors, similar to the one used in the present
trial. However, in that trial, gait was performed outdoors,
and patients were asked to initially perform a 100-m
warm-up walk before a second 100-m walk was per-
formed to collect data. It is possible that walking 200 m
may have induced fatigue in some patients, which may
have negatively influenced the data analysis. The 60-m
distance selected in the present study seemed to be a
reasonable walking distance to assess patients with knee
OA. Nevertheless, Lester and Zhang reported a walking
speed of 1.12 m/s, a step length of 0.63 m, and a cadence
of 106steps/min at 3 weeks after the final HA injection,
which are equivalent to our findings. However, their trial
did not have a control group for comparison. Of the
other four studies, one did not report gait scores [30],
one expressed the delta between follow-up moments for
the gait speed (i.e., no absolute values) [31], one reported
normalized gait velocity and step length according to
body height [34], and Skwara et al. [29] presented abso-
lute values for walking speed and stride length and ob-
served a walking speed of 1.16 m/s, similar to that
reported by Lester and Zhang. However, the results may
not be comparable, since the follow-up assessment was
performed at 12 weeks.
In the present study, the mean increase in gait speed
(0.076m/s) found in the HA +mannitol group at 4 weeks
Fig. 1 CONSORT patient dissemination flow chart
Table 1 Patient demographics
HA +mannitol (n = 9) HA + sorbitol (n = 5) Saline (n = 8) Total (n = 22)
Gender: male (n, %) 6 (67%) 1 (20%) 5 (63%) 12 (55%)
Gender: female (n, %) 3 (33%) 4 (80%) 3 (37%) 10 (45%)
Age (years), mean ± std. dev 50.8 ± 11.7 56.4 ± 13.0 54.8 ± 12.3 53.50 ± 11.9
Body mass index (kg/m2), mean ± std. dev 29.0 ± 4.6 26.8 ± 3.4 28.7 ± 4.0 28.4 ± 4.1
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post-injection is thought to be clinically relevant. This
increase in walking speed is 13% greater than the mean
difference in walking speed between healthy subjects
and those with knee OA, based on data from a recent
meta-analysis [21]. Interestingly, increases in gait vel-
ocity and cadence have also been reported following a
local injection of anesthesia in subjects with knee OA
[36]. Thus, pain reduction is likely a key factor in the ef-
ficacy of viscosupplementation in improving gait.
Four of the previous studies used multiple injections of
HA. Only the present trial and the study by Skwara et al.
[29] evaluated the effects of a single bolus of viscosupple-
mentation through gait analysis. Repeated viscosupplementa-
tion not only improves knee OA symptoms between
injection cycles, but also exerts a marked carry-over effect
for at least 1 year post-administration [37]. Delivering a sin-
gle injection allows for shorter follow-up periods and poten-
tially decreased overall healthcare costs. Based on clinical
experience, we believed that a single bolus injection could
significantly change gait pattern and alleviate patients’ symp-
toms. The results of this pilot study support this hypothesis
and the need for a large, randomized, controlled, clinical trial
to assess the effectiveness of a single-bolus HA injection in
people with knee OA. This hypothesis is also supported by a
pilot, open, non-comparative study that demonstrated re-
duced joint pain and increased function in 79 patients with
knee OA at 6 months following a single intra-articular injec-
tion of non-crosslinked HA [38]. HA injections studied a
decade ago did not employ the same compounds used today.
Viscosupplements are continually evolving; the newer prod-
ucts with stabilizer additives are expected to exert an
anti-free radical effect, which could potentially decrease a
local inflammatory reaction in the knee and impart greater
efficacy with a single intra-articular injection.
While gait patterns demonstrated statistically signifi-
cant differences at 4 weeks following HA injection com-
pared to baseline, there were no significant differences
in self-reported WOMAC, EQ-5D-VAS, VAS pain, or
Table 2 Gait parameters for patients who received injections of HA +mannitol, HA + sorbitol, or saline, pre-injection (visit 1) and
4 weeks post-injection (visit 2)
HA +mannitol (n = 9) HA + sorbitol (n = 5) Saline (n = 8)
Baseline 4 weeks Baseline 4 weeks Baseline 4 weeks
Walking speed (m/s), mean (SD) 1.096 (0.211) 1.367 (0.183) 1.122 (0.213) 1.239 (0.175) 1.185 (0.219) 1.237 0.185)
Stride length (m), mean (SD) 1.314 (0.180) 1.367 (0.183) 1.217 (0.181) 1.239 (0.175) 1.273 (0.180) 1.311 (0.144)
Cadence (steps/minute), mean (SD) 49.764 (4.335) 50.986 (4.781) 55.011 (3.204) 54.175 (2.546) 55.579 (3.944) 56.426 (3.470)
Swing duration (% gait cycle), mean (SD) 40.835 (2.231) 39.673 (2.736) 41.000 (1.959) 40.735 (1.815) 39.936 (2.120) 40.245 (2.426)
Fig. 2 Changes in gait parameters from baseline to 4W post-injection (i.e., post-injection value minus baseline value) for the HA +mannitol group
(HA + M), HA + sorbitol group (HA + S), and the saline group. Data are presented as medians (dot) and interquartile ranges (vertical lines).
Significant changes between baseline and 4W are indicated with solid lines, whereas non-significant changes are indicated with dashed lines
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VAS stiffness scores in the present trial. A 4-week as-
sessment was deemed adequate, as the intra-articular
half-life of HA is less than 2 days. In contrast, Kotevoglu
et al. [35] reported improvements in WOMAC physical
function and WOMAC stiffness scores induced by both
sodium hyaluronate and hylan G-F 20 at 1 month
post-injection in a randomized clinical trial of 59 pa-
tients that remained significant at 6 months (p < 0.01).
Thus, a single HA injection appears to have a positive
impact on pain and function up to 6 months following
injection. This is corroborated by electromyography, in
which HA injection effectively decreased co-contraction
and improved motor activity of the lower extremity
muscles for up to 6 months [33]. The absence of consist-
ent significant differences in self-reported outcome mea-
sures and the presence of statistically significant
differences in gait patterns during walking tests under-
line the importance of using gait analysis when assessing
the management of knee OA. In a gender-specific study
of OA of the knee, patient-reported measures only par-
tially reflected sex differences consistently observed with
physical impairment and performance-based measures
[20]. Thus, a comprehensive functional assessment in
patients with OA should include physical impairment,
performance, and self-reported parameters of knee
function.
This pilot study was designed to evaluate the feasibility
of scientific outcomes, i.e., the gait parameters most
relevant for the assessment of polyol-containing HA
injection in people with knee OA. According to Thabane
et al. [39], pilot studies can also assess feasibility out-
comes for the study process, resources, and manage-
ment. A secondary feasibility outcome around this
study’s process, specifically patient recruitment, became
evident during its conduct. Many patients were unwill-
ing to participate, as they did not want to risk being allo-
cated to the placebo group because they were in pain, a
common concern in trials investigating OA interven-
tions [40]. In contrast to other trials, [31] the present
study did not introduce any rescue medication following
the injection, to avoid additional confounding variables.
The pain management protocol will be reviewed and
may be revised for future trials, to perhaps compare out-
comes of a single HA injection versus multiple injections
and avoid having a placebo group.
This study has limitations. A sample size of 22 patients
is informative for evaluating feasibility outcomes, but is
a limitation for statistical analysis, even in a pilot study.
Based on the results presented herein, power calcula-
tions indicate that a future trial designed to detect a dif-
ference between groups of 0.076 m/s on walking speed,
0.055 m on stride length, and 15 points on the KSS
would require a sample of 37, 26, and 17 participants
per group, respectively (alpha 0.05, beta 0.8). The HA +
sorbitol group included only 5 participants, compared to
9 and 8 participants in the other two groups, limiting
comparisons. Also, the HA +mannitol group was, on
average, 4 to 5 years younger than the other two groups,
Fig. 3 Changes in clinical outcome measure scores from baseline to 4W post-injection for the HA +mannitol group (HA +M), the HA + sorbitol
group (HA + S), and the saline group. Data are presented as medians (dots) and interquartile ranges (vertical lines). Significant changes from
baseline to 4W are indicated with solid lines, whereas non-significant changes are indicated with dashed lines
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which may have contributed to the observed improve-
ments in gait speed and stride length. The present study
did not encourage the use of a medication diary during
the follow-up period. Including an observation period of
1–2 weeks may have helped to distinguish the “trial” effect
from placebo, or the attention control effect. Intrinsic pa-
tient factors such as obesity, anxiety, and depression are
also associated with poor WOMAC scores and walking
times [41, 42]. This study ensured that BMI was similar
among all three groups, but it did not account for psycho-
logical factors such as anxiety and depression that could
influence the final outcome.
Conclusions
Gait analysis is proposed as a complementary outcome
measure to the standard patient-reported scores and
physical measures for testing the effectiveness of HA in-
jection, with gait speed and stride length as the most
relevant parameters for investigation. The results of this
study support the need for a larger, randomized, con-
trolled, clinical trial, with at least 37 participants per
group, to assess the effectiveness of a single-bolus HA
injection versus multiple injections in people with knee
OA using both gait performance and self-reported pa-
rameters of knee function.
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